Dermorphin

D-alanine at position 2 of dermorphin serves two functions. First, it contributes to mu-opioid receptor binding geometry -- the D-configuration allows the peptide backbone to adopt a conformation that fits the receptor binding site with high affinity. This contributes to dermorphin's exceptional potency. Second, D-amino acids are resistant to most mammalian peptidases, which are stereospecific for L-amino acids. This resistance slows degradation and extends dermorphin's activity compared to endorphins with the same receptor affinity. Together these properties explain why a frog skin peptide achieves opioid potency orders of magnitude above morphine.

Dermorphin serves as a high-affinity mu-opioid receptor tool compound, useful for receptor binding assays, pharmacological characterization of mu-receptor subtypes (mu1 vs. mu2), autoradiography studies of opioid receptor distribution, and as a positive control in opioid receptor assays. Its exceptional potency makes it useful at very low concentrations. Dermorphin analogues have also been developed as templates for novel analgesic design, and studying dermorphin's pharmacophore has contributed to understanding what structural features drive mu-receptor selectivity and potency.

Dermorphin was discovered in 1981 by Vittorio Erspamer's group in Rome, who had systematically studied the pharmacological properties of skin secretions from South American phyllomedusine frogs for decades. Erspamer's laboratory is responsible for identifying multiple bioactive peptides from amphibian skin (including bombesin, caerulein, and physalaemin). Phyllomedusa sauvagii skin secretions showed opioid-like activity in bioassays, and the active peptide was isolated and characterized as a novel heptapeptide with the remarkable D-amino acid in position 2. The discovery prompted investigation into how organisms incorporate D-amino acids into peptides -- a question that later revealed the epimerization enzymes responsible.